Medivation, Inc. (MDVN)

81.44
NASDAQ
Prev Close 81.44
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)

Latest News

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

How I'd Play Biotech Buyout Rumors

How I'd Play Biotech Buyout Rumors

Answering questions from the Biotech Mailbag on FLXN and SGYP.

Biotech Buoyed by Deal Talk

Biotech Buoyed by Deal Talk

M&A activity is in a serious upswing, and here are some names to watch.

Vigorous M&A Activity Signals Economic Health

Vigorous M&A Activity Signals Economic Health

Despite markets at record highs, companies are satisfying their appetites to grow and find value by buying others.

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Portfolio Manager: Is Pfizer Acquiring Too Quickly?

Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer Is Buying a Portion of AstraZeneca's Antibiotics Business

Pfizer is making another acquisition.

Market Keeps Chasing Its Own Tail

Market Keeps Chasing Its Own Tail

Stocks travel a good distance just to end up nowhere.

Rounding Third and Heading Home

It was nice to fill in for Doug Kass on what was a very uneventful Monday to begin the week. The market traded in an extremely narrow range for the day, and outside the strength in biotech and the weakness in oil after a nice recent rally there real...

Whole Lotta Yield-Chasing Going On

Markets continue to trade in a very narrow range and remain largely directionless. Interesting story of the day: Distressed debt billionaire and investor Wilbur Ross buying hundreds of millions of dollars in distressed energy debt in a bid to take c...

Cramer: A Bunch of Semis Are Ripe for the Picking

Cramer: A Bunch of Semis Are Ripe for the Picking

That's the hot spot in M&A right now.

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's Deal to Buy Medivation May Give the Company Its Groove Back

Pfizer's $14 billion acquisition of Medivation is a strong purchase, according to Jim Cramer, who now wonders what Sanofi will do next.

Biotechs Continue to Lead a Listless Market

Stocks are back to flat to slightly lower overall, but biotechs are up some 1.5% following the announcement from Pfizer of plans to buy Medivation for $14 billion. Gilead Sciences is getting some flak for not pursuing Medivation more heavily, but I ...

Facebook Stands Out and FormFactor Has a Good Start

Facebook Stands Out and FormFactor Has a Good Start

Overall, this is still a good environment for stock picking.

Biotechs Rally on Pfizer/Medivation Deal

The market is basically flat across the board to start the new week, but biotechs are strong overall in early going following news that Pfizer plans to buy Medivation for $14 billion. The sector's movers include some biotechs that I hold. For instan...

Pfizer Is Buying Medivation for $14 Billion

Pfizer Is Buying Medivation for $14 Billion

Pfizer confirmed its $14 billion acquisition of cancer drugmaker Medivation on Monday.

Morning Movers: PFE, VRX, VIAB, FL, UA

Morning Movers: PFE, VRX, VIAB, FL, UA

Pfizer agrees to acquire Medivation while Citi puts Foot Locker and Under Armour on the back-to-school shopping list.

Bret Jensen Reporting for Duty

Good morning, Bret Jensen here! It's good to be standing in for Doug Kass again on the daily diary as we begin a new trading week. Biotech -- my favorite subject -- should be a hot topic today after Pfizer appears to have outbid Sanofi for oncology ...

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

Pfizer Buys Medivation, the Crown Jewel in Cancer Therapy

A potential blockbuster drug deal is reportedly in the works.

Medivation downgraded at JMP

It's 'All Systems Go' for Biotech

It's 'All Systems Go' for Biotech

The sector seems to be rebounding after tumbling by more than 40%.

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Investors Scour Big Pharma M&A Scene for Next Big Takeover

Following Galenica's $1.5 billion bid for Relypsa, investors are beginning to search for the next target.

Cramer: 11 Reasons Why the Market Turned

Cramer: 11 Reasons Why the Market Turned

All of these add up to a level of insecurity on the part of sidelined money.

Cramer: 5 Market Themes for the Rest of 2016

Cramer: 5 Market Themes for the Rest of 2016

It's a pretty broad spectrum, but they've definitely arrived.

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

Stocks Feeling the Pressure of 'Brexit', Italian Banks Weakness

There are renewed worries about Brexit as the British pound has fallen to a new 30 year low.

Biotech M&A Waking Up After Long Nap

Biotech M&A Waking Up After Long Nap

The uptick in the small- and mid-cap space bodes well for future capital appreciation.

2 Promising Biopharmas Reach Key Junctures

2 Promising Biopharmas Reach Key Junctures

FDA decision will impact Relypsa's buyout potential while Aritana won't stay this undervalued.